RxDoctor Payments Data

Rebecca Scandrett, MD

Interventional Cardiology · Waterbury, CTNPI 1972720522

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,514 of the $2,092 with a category attached, or 72.4%. Medtronic accounts for 92.6% of it on its own, with 6 other manufacturers making up the rest. That places this record below the midpoint for interventional cardiology clinicians in CT, where the typical reported total is $5,446.

$2,092in general payments, 2019–2025

Across 23 payments — averaging $90.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Pfizer$57
  • Abbott$25
  • E.r. Squibb & Sons, L.L.C.$23
  • Boston Scientific$18
  • Amgen$17
  • plus $13 from 1 others

What the payments were for

  • Travel & lodging$1,51472%
  • Food & beverage$57828%

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,092 in reported general payments places this provider in the 25th percentile of 73 interventional cardiology providers in Connecticut.

See all interventional cardiology providers in Connecticut

Medicare billing

Part B allowed, 2024
$94,097
Medicare patients
573
Services billed
1,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban212$263,102
XareltoRivaroxaban59$95,336
EntrestoSacubitril/Valsartan48$54,194
FarxigaDapagliflozin Propanediol41$42,272
Repatha SureclickEvolocumab23$20,113
BrilintaTicagrelor17$18,238
Praluent PenAlirocumab16$16,071
Metoprolol Succinate344$4,103
Rosuvastatin Calcium257$3,234
Atorvastatin Calcium310$3,003
Ezetimibe118$2,214
Amlodipine Besylate227$1,462
Carvedilol157$1,315
Diltiazem 24hr Er (Cd)Diltiazem Hcl40$1,260
Losartan Potassium159$1,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$57$263,102212 claims
AstraZenecaFarxiga, Brilinta$13$60,51058 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 73 interventional cardiology providers in Connecticut.

Other interventional cardiology in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →